RxSight, Inc. RXST
4.66
(0.07)
(1.48%)
as of 25 Sep
- Market cap
- $196.7M
- P/E
- 0.0×
Follow RXST
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(12.92%) | (13.99%) | (17.06%) | (17.35%) | |
| (11.54%) | (12.36%) | (15.12%) | (14.19%) | ||
ROIC |
(58.67%) | (63.34%) | (70.00%) | (63.16%) | |
Return on Tangible Assets |
(13.01%) | (14.20%) | (17.59%) | (17.99%) | |
Average Days of Receivables |
62.04 | 63.47 | 64.26 | 224.64 | |
Free Cash Flow per Share |
(0.54) | (0.47) | (0.52) | (0.65) | |
Free Cash Flow |
(22.19) | (19.34) | (21.58) | (27.16) | |
Capital Expenditures |
(3.54) | (3.83) | (4.01) | (4.43) | |
Piotroski F-Score |
4.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(3.71%) | (3.08%) | (3.62%) | (4.81%) | |
Accounts Receivable Turnover |
5.74 | 5.03 | 4.77 | 2.39 | |
Accounts Payable Turnover |
8.93 | 6.40 | 4.12 | 5.92 | |
Inventory Turnover |
1.40 | 1.18 | 1.00 | 0.92 | |
Average Days of Payables |
34.67 | 61.42 | 88.75 | 80.67 | |
Days of Inventory on Hand |
297.22 | 366.03 | 434.39 | 471.93 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
27.34% | 28.67% | 29.54% | 28.75% | |
Selling, General and Administrative Expense of Revenue |
79.65% | 83.77% | 90.89% | 91.95% | |
Share Based Compensation of Revenue |
21.87% | 23.51% | 25.43% | 24.56% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.52 | 0.40 | 0.38 | 0.48 | |
Depreciation/Fixed assets |
(0.49) | (0.40) | (0.35) | (0.29) | |
Capex/Depreciation |
0.55 | 0.73 | 0.86 | 1.10 | |
Revenue per Share |
3.47 | 3.29 | 3.09 | 3.07 | |
Operating CF per Share |
(0.46) | (0.38) | (0.43) | (0.55) | |
Capex per Share |
(0.09) | (0.09) | (0.10) | (0.11) | |
Capex to Sales |
0.02 | 0.03 | 0.03 | 0.03 | |
Net Profit Margin |
(25.15%) | (28.96%) | (36.59%) | (36.80%) |
Columns are period end dates